EDIT241220C1000
- 0.00
- 0.000.00%
Editas Medicine Newsroom
Clear Street Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $4
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Cuts Target Price to $5
Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5
J.P. Morgan Downgrades Editas Medicine(EDIT.US) to Sell Rating
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)
Morgan Stanley Maintains Editas Medicine(EDIT.US) With Hold Rating
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $3
Editas Medicine Is Maintained at Sector Perform by RBC Capital
RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4
Editas Medicine Maintains Hold Rating Amid Strategic Shifts and Financial Challenges
A Quick Look at Today's Ratings for Editas Medicine(EDIT.US), With a Forecast Between $3 to $8
RBC Cuts Price Target on Editas Medicine to $4 From $5, Keeps Sector Perform, Speculative Risk
Stifel Downgrades Editas Medicine to Hold, Lowers Price Target to $3
Editas Medicine Analyst Ratings
Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)
Editas Medicine (EDIT) Receives a Buy From TD Cowen
Editas Medicine: Navigating Uncertainty With a Hold Rating Amid Strategic Shifts and Development Challenges
Editas Medicine Cut to Equal-Weight From Overweight by Wells Fargo
Editas Medicine Analyst Ratings
Wells Fargo Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $4